A citation-based method for searching scientific literature

Scott J Rodig, Mari Mino-Kenudson, Sanja Dacic, Beow Y Yeap, Alice Shaw, Justine A Barletta, Hannah Stubbs, Kenny Law, Neal Lindeman, Eugene Mark, Pasi A Janne, Thomas Lynch, Bruce E Johnson, A John Iafrate, Lucian R Chirieac. Clin Cancer Res 2009
Times Cited: 476







List of co-cited articles
792 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
49

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
46

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Alice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, Subba R Digumarthy, Daniel B Costa, Rebecca S Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott,[...]. J Clin Oncol 2009
43

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
43

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall,[...]. N Engl J Med 2013
42

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, A John Iafrate, Marileila Varella-Garcia, Stephen B Fox, Gregory J Riely, Benjamin Solomon, Sai-Hong I Ou, Dong-Wan Kim,[...]. Lancet Oncol 2012
887
23

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
921
23

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Jean-Charles Soria, Daniel S W Tan, Rita Chiari, Yi-Long Wu, Luis Paz-Ares, Juergen Wolf, Sarayut L Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu,[...]. Lancet 2017
503
22

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.
Mari Mino-Kenudson, Lucian R Chirieac, Kenny Law, Jason L Hornick, Neal Lindeman, Eugene J Mark, David W Cohen, Bruce E Johnson, Pasi A Jänne, A John Iafrate,[...]. Clin Cancer Res 2010
336
20

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
Daisy Wing-Sze Wong, Elaine Lai-Han Leung, Kimpton Kam-Ting So, Issan Yee-San Tam, Alan Dart-Loon Sihoe, Lik-Cheung Cheng, Kwok-Keung Ho, Joseph Siu-Kie Au, Lap-Ping Chung, Maria Pik Wong. Cancer 2009
529
18

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
Jussi P Koivunen, Craig Mermel, Kreshnik Zejnullahu, Carly Murphy, Eugene Lifshits, Alison J Holmes, Hwan Geun Choi, Jhingook Kim, Derek Chiang, Roman Thomas,[...]. Clin Cancer Res 2008
698
18

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
Justin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, Sheheryar Kabraji, Mark M Awad, Ryohei Katayama, Amanda Pawlak, Mari Mino-Kenudson, Beow Y Yeap, Gregory J Riely,[...]. Clin Cancer Res 2013
356
17

Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
Florian Cabillic, Audrey Gros, Frédéric Dugay, Hugues Begueret, Laura Mesturoux, Dan Cristian Chiforeanu, Leila Dufrenot, Vincent Jauffret, Dominique Dachary, Romain Corre,[...]. J Thorac Oncol 2014
126
16

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Shirish M Gadgeel, Leena Gandhi, Gregory J Riely, Alberto A Chiappori, Howard L West, Michele C Azada, Peter N Morcos, Ruey-Min Lee, Linta Garcia, Li Yu,[...]. Lancet Oncol 2014
465
16

Ceritinib in ALK-rearranged non-small-cell lung cancer.
Alice T Shaw, Dong-Wan Kim, Ranee Mehra, Daniel S W Tan, Enriqueta Felip, Laura Q M Chow, D Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas,[...]. N Engl J Med 2014
994
16

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
515
16

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
16

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
Antonio Marchetti, Alessia Di Lorito, Maria Vittoria Pace, Manuela Iezzi, Lara Felicioni, Tommaso D'Antuono, Giampaolo Filice, Luigi Guetti, Felice Mucilli, Fiamma Buttitta. J Thorac Oncol 2016
89
17

ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
968
15

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Ryohei Katayama, Alice T Shaw, Tahsin M Khan, Mari Mino-Kenudson, Benjamin J Solomon, Balazs Halmos, Nicholas A Jessop, John C Wain, Alan Tien Yeo, Cyril Benes,[...]. Sci Transl Med 2012
865
15

An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators.
Murry W Wynes, Lynette M Sholl, Manfred Dietel, Ed Schuuring, Ming S Tsao, Yasushi Yatabe, Raymond R Tubbs, Fred R Hirsch. J Thorac Oncol 2014
116
15

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.
Kentaro Inamura, Kengo Takeuchi, Yuki Togashi, Satoko Hatano, Hironori Ninomiya, Noriko Motoi, Ming-yon Mun, Yukinori Sakao, Sakae Okumura, Ken Nakagawa,[...]. Mod Pathol 2009
325
15

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura,[...]. Lancet 2017
419
15

Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
Jin Ho Paik, Gheeyoung Choe, Hyojin Kim, Ji-Young Choe, Hyun Ju Lee, Choon-Taek Lee, Jong Seok Lee, Sanghoon Jheon, Jin-Haeng Chung. J Thorac Oncol 2011
223
14

Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.
Lynette M Sholl, Stanislawa Weremowicz, Stacy W Gray, Kwok-Kin Wong, Lucian R Chirieac, Neal I Lindeman, Jason L Hornick. J Thorac Oncol 2013
115
14

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.
Kengo Takeuchi, Young Lim Choi, Yuki Togashi, Manabu Soda, Satoko Hatano, Kentaro Inamura, Shuji Takada, Toshihide Ueno, Yoshihiro Yamashita, Yukitoshi Satoh,[...]. Clin Cancer Res 2009
513
14

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
Kentaro Inamura, Kengo Takeuchi, Yuki Togashi, Kimie Nomura, Hironori Ninomiya, Michiyo Okui, Yukitoshi Satoh, Sakae Okumura, Ken Nakagawa, Manabu Soda,[...]. J Thorac Oncol 2008
340
14

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Robert C Doebele, Amanda B Pilling, Dara L Aisner, Tatiana G Kutateladze, Anh T Le, Andrew J Weickhardt, Kimi L Kondo, Derek J Linderman, Lynn E Heasley, Wilbur A Franklin,[...]. Clin Cancer Res 2012
758
14

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
Daniel B Costa, Susumu Kobayashi, Shuchi S Pandya, Wee-Lee Yeo, Zhongzhou Shen, Weiwei Tan, Keith D Wilner. J Clin Oncol 2011
424
14

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Daniel B Costa, Alice T Shaw, Sai-Hong I Ou, Benjamin J Solomon, Gregory J Riely, Myung-Ju Ahn, Caicun Zhou, S Martin Shreeve, Paulina Selaru, Anna Polli,[...]. J Clin Oncol 2015
399
14

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Alice T Shaw, Tae Min Kim, Lucio Crinò, Cesare Gridelli, Katsuyuki Kiura, Geoffrey Liu, Silvia Novello, Alessandra Bearz, Oliver Gautschi, Tony Mok,[...]. Lancet Oncol 2017
254
14

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
Kengo Takeuchi, Young Lim Choi, Manabu Soda, Kentaro Inamura, Yuki Togashi, Satoko Hatano, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Yukitoshi Satoh,[...]. Clin Cancer Res 2008
361
13

Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
Hyojin Kim, Seol-Bong Yoo, Ji-Young Choe, Jin Ho Paik, Xianhua Xu, Hiroaki Nitta, Wenjun Zhang, Thomas M Grogan, Choon-Taek Lee, Sanghoon Jheon,[...]. J Thorac Oncol 2011
122
13

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Alice T Shaw, Leena Gandhi, Shirish Gadgeel, Gregory J Riely, Jeremy Cetnar, Howard West, D Ross Camidge, Mark A Socinski, Alberto Chiappori, Tarek Mekhail,[...]. Lancet Oncol 2016
430
13

Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.
Chris M J Conklin, Kenneth J Craddock, Cherry Have, Janessa Laskin, Christian Couture, Diana N Ionescu. J Thorac Oncol 2013
152
13

Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.
Marina Pekar-Zlotin, Fred R Hirsch, Lior Soussan-Gutman, Maya Ilouze, Addie Dvir, Theresa Boyle, Murry Wynes, Vincent A Miller, Doron Lipson, Gary A Palmer,[...]. Oncologist 2015
109
13

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li,[...]. Cell 2007
12

Comprehensive histologic analysis of ALK-rearranged lung carcinomas.
Akihiko Yoshida, Koji Tsuta, Harumi Nakamura, Takashi Kohno, Fumiaki Takahashi, Hisao Asamura, Ikuo Sekine, Masashi Fukayama, Tatsuhiro Shibata, Koh Furuta,[...]. Am J Surg Pathol 2011
206
12

Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.
Spasenija Savic, Joachim Diebold, Anne-Katrin Zimmermann, Wolfram Jochum, Betty Baschiera, Susanne Grieshaber, Luigi Tornillo, Bettina Bisig, Keith Kerr, Lukas Bubendorf. Lung Cancer 2015
59
20

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
Young Lim Choi, Manabu Soda, Yoshihiro Yamashita, Toshihide Ueno, Junpei Takashima, Takahiro Nakajima, Yasushi Yatabe, Kengo Takeuchi, Toru Hamada, Hidenori Haruta,[...]. N Engl J Med 2010
837
12

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
Sai-Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, Ramaswamy Govindan, James Chih-Hsin Yang, Brett Hughes, Hervé Lena, Denis Moro-Sibilot, Alessandra Bearz, Santiago Viteri Ramirez,[...]. J Clin Oncol 2016
406
12

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Alice T Shaw, Beow Y Yeap, Benjamin J Solomon, Gregory J Riely, Justin Gainor, Jeffrey A Engelman, Geoffrey I Shapiro, Daniel B Costa, Sai-Hong I Ou, Mohit Butaney,[...]. Lancet Oncol 2011
668
12

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Neal I Lindeman, Philip T Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Dacic, Giuseppe Giaccone, Robert Brian Jenkins, David J Kwiatkowski, Juan-Sebastian Saldivar, Jeremy Squire,[...]. J Thorac Oncol 2013
536
12

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
12

Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.
Christina I Selinger, Toni-Maree Rogers, Prudence A Russell, Sandra O'Toole, Poyee Yip, Gavin M Wright, Zoe Wainer, Lisa G Horvath, Michael Boyer, Brian McCaughan,[...]. Mod Pathol 2013
115
11

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
Tsuyoshi Takahashi, Makoto Sonobe, Masashi Kobayashi, Akihiko Yoshizawa, Toshi Menju, Ei Nakayama, Nobuya Mino, Shotaro Iwakiri, Kiyoshi Sato, Ryo Miyahara,[...]. Ann Surg Oncol 2010
252
11

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.
D Ross Camidge, Scott A Kono, Antonella Flacco, Aik-Choon Tan, Robert C Doebele, Qing Zhou, Lucio Crino, Wilbur A Franklin, Marileila Varella-Garcia. Clin Cancer Res 2010
260
11

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Dong-Wan Kim, Ranee Mehra, Daniel S W Tan, Enriqueta Felip, Laura Q M Chow, D Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Gregory J Riely,[...]. Lancet Oncol 2016
279
11

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
Takashi Seto, Katsuyuki Kiura, Makoto Nishio, Kazuhiko Nakagawa, Makoto Maemondo, Akira Inoue, Toyoaki Hida, Nobuyuki Yamamoto, Hiroshige Yoshioka, Masao Harada,[...]. Lancet Oncol 2013
414
11

Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.
Anne McLeer-Florin, Denis Moro-Sibilot, Adrien Melis, Dimitri Salameire, Christine Lefebvre, Françoise Ceccaldi, Florence de Fraipont, Elisabeth Brambilla, Sylvie Lantuejoul. J Thorac Oncol 2012
157
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.